Generic Name: etonogestrel
Brand Name: Nexplanon
Manufacturer: Merck Canada Inc.
Therapeutic Area: Prevention of pregnancy
Indications: Indicated for the prevention of pregnancy for up to 3 years
Manufacturer Requested Reimbursement Criteria1: Indicated for the prevention of pregnancy for up to 3 years
Submission Type: Initial
NOC Status at Filing: Post NOC
Project Status: Complete
Companion Diagnostics: No
Date Recommendation Issued: October 20, 2020
Recommendation Type: Reimburse with clinical criteria and/or conditions
Fee Schedule: Schedule A
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Key Milestones2 | |
|---|---|
| Call for patient input open | May 06, 2020 |
| Call for patient input closed | June 25, 2020 |
| Clarification: - No patient input submission received | |
| Submission received | June 03, 2020 |
| Clarification: Submission was previously withdrawn and has been refiled by the sponsor | |
| Submission accepted | June 17, 2020 |
| Review initiated | June 18, 2020 |
| Draft CADTH review report(s) provided to sponsor for comment | July 31, 2020 |
| Deadline for sponsors comments | August 12, 2020 |
| CADTH responses on draft review report(s) provided to sponsor | September 03, 2020 |
| Expert committee meeting (initial) | September 16, 2020 |
| Draft recommendation issued to sponsor | September 28, 2020 |
| End of embargo period | October 13, 2020 |
| Final recommendation issued to sponsor and drug plans | October 20, 2020 |
| Final recommendation posted | October 22, 2020 |
| Deadline for sponsor to submit redaction requests on draft CADTH review report(s) | November 03, 2020 |
| CADTH review report(s) posted | December 07, 2020 |